Houston dermatology clinicians compared severity scoring, JAK inhibitor safety data, and psychosocial counseling strategies across 3 alopecia areata patient cases.
|Articles|June 1, 2006
Melamoma, sun linked
Santa Monica, Calif. - Fifty years of medical studies showthat sun exposure is a primary component in the development ofmelanoma, according to the April issue of Dermatologic Surgery.
Advertisement
Santa Monica, Calif. - Fifty years of medical studies show that sun exposure is a primary component in the development of melanoma, according to the April issue of Dermatologic Surgery.
While it is unclear what pattern of sun exposure is linked to melanoma, or whether that exposure is short, intense intermittent or cumulative, the sun acts as an initiating and promoting agent and causes immunosuppression, researchers say.
Advertisement
Related to this article
Preview the trial data dermatology NPs and PAs will dissect in small-group sessions on AD, psoriasis, and type 2 disease at Horizons in Advanced Practice.
The September issue highlights advances in alopecia areata, cosmetic SPF, psoriasis treatment, teledermatology, and atopic dermatitis.
Phase 3 data show intismeran plus pembrolizumab reduced recurrence or death risk by 42% in patients with resected stage IIB-IV melanoma.
The 3rd annual meeting in Atlanta gives dermatology NPs and PAs 4 case-based breakout sessions and a general education session in a focused, small-group setting.
Shannon Trotter, DO, moderated a Dermatology Times Case-Based Roundtable event on how pharmacokinetics, adverse event timing, and trial response criteria should shape hedgehog pathway inhibitor selection in advanced BCC.
Cosibelimab-ipdl is now an NCCN Category 2A option for locally advanced CSCC in patients ineligible for curative surgery or radiation.
Lutikizumab significantly improved HiSCR75 response, pain, and disease flares in adults and adolescents with moderate to severe HS.
Advertisement
Advertisement
Trending on Dermatology Times
1
Lutikizumab Meets Primary End Point in Phase 3 HS Trial
2
Intismeran Plus Pembrolizumab Improves RFS in Melanoma
3
AAD, HS Foundation Issue First Joint Hidradenitis Suppurativa Guidelines
4
Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
5